Wall Street analysts predict that Cytosorbents Co. (NASDAQ:CTSO – Get Rating) will report sales of $9.17 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Cytosorbents’ earnings, with the highest sales estimate coming in at $10.20 million and the lowest estimate coming in at $7.87 million. Cytosorbents reported sales of $12.02 million in the same quarter last year, which indicates a negative year-over-year growth rate of 23.7%. The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Cytosorbents will report full year sales of $39.82 million for the current year, with estimates ranging from $36.77 million to $42.60 million. For the next fiscal year, analysts expect that the firm will post sales of $50.26 million, with estimates ranging from $41.67 million to $57.20 million. Zacks’ sales averages are an average based on a survey of research firms that that provide coverage for Cytosorbents.
Cytosorbents (NASDAQ:CTSO – Get Rating) last issued its earnings results on Tuesday, May 3rd. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). Cytosorbents had a negative return on equity of 44.65% and a negative net margin of 71.16%. During the same quarter in the previous year, the firm earned ($0.10) earnings per share.
Shares of Cytosorbents stock opened at $2.11 on Friday. The stock has a market capitalization of $91.91 million, a PE ratio of -3.10 and a beta of 0.48. Cytosorbents has a 52-week low of $1.78 and a 52-week high of $9.80. The company has a 50-day simple moving average of $2.66 and a two-hundred day simple moving average of $3.76.
Several hedge funds have recently made changes to their positions in CTSO. BlackRock Inc. grew its position in Cytosorbents by 2.8% during the fourth quarter. BlackRock Inc. now owns 2,631,210 shares of the medical research company’s stock valued at $11,024,000 after buying an additional 72,418 shares during the period. Skylands Capital LLC grew its position in Cytosorbents by 9.3% during the first quarter. Skylands Capital LLC now owns 2,127,952 shares of the medical research company’s stock valued at $6,788,000 after buying an additional 181,578 shares during the period. Avenir Corp grew its position in Cytosorbents by 28.1% during the fourth quarter. Avenir Corp now owns 1,787,275 shares of the medical research company’s stock valued at $7,489,000 after buying an additional 391,890 shares during the period. Neuberger Berman Group LLC grew its position in Cytosorbents by 48.8% during the third quarter. Neuberger Berman Group LLC now owns 1,260,574 shares of the medical research company’s stock valued at $10,203,000 after buying an additional 413,485 shares during the period. Finally, Granahan Investment Management LLC grew its position in Cytosorbents by 10.0% during the first quarter. Granahan Investment Management LLC now owns 1,215,928 shares of the medical research company’s stock valued at $3,879,000 after buying an additional 110,321 shares during the period. Hedge funds and other institutional investors own 40.98% of the company’s stock.
Cytosorbents Company Profile (Get Rating)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.
- Get a free copy of the StockNews.com research report on Cytosorbents (CTSO)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.